Recombinant Human monoclonal antibody expressed in CHO binding to Human FGFR2. This is a novel fibroblast growth factor receptor 2 (FGFR2) directed antibody used for cancer therapy. FGFR2 is expressed in a range of tumor types such as gastric, breast, HNSCC, pancreatic and ovarian cancers. FGFR2 has been described to promote tumor growth and survival and play a role in chemotherapy resistance.
Figure 1 The FGFR2-specific Ab (BAY 1179470) induces FGFR2 internalization and degradation in vitro.
Fluorescence immunocytochemistry was used to evaluate the FGFR2-Ab-induced internalization of FGFR2 in cells with high (SUM-52PE) FGFR2 expression.
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G., ... & Braun, M. (2016). Preclinical efficacy of the auristatin-based antibody–drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer research, 76(21), 6331-6339.
Figure 2 Antitumor efficacy of FGFR2-ADC in OV30-0511A ovarian cancer PDX model.
Immunoblot indicates a high level of FGFR2 protein expression in the OV30-0511A model.
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G., ... & Braun, M. (2016). Preclinical efficacy of the auristatin-based antibody–drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer research, 76(21), 6331-6339.
Figure 3 Localization of Cypher 5E-labeled FGFR2-Ab (red) 6 hours after incubation with live SUM-52PE cells and subsequent staining with anti-Rab7.
Yellow regions indicate colocalization. Blue DNA stain indicates the nucleus.
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G., ... & Braun, M. (2016). Preclinical efficacy of the auristatin-based antibody–drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer research, 76(21), 6331-6339.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B026(A) | Recombinant Anti-human FGFR2 Intrabody [(D-Arg)9] | IF, FC, FuncS | scFv-(D-Arg)9 |
IAB-B026(G) | Recombinant Anti-human FGFR2 Intrabody [+36 GFP] | WB, ICC, FuncS | scFv-(+36GFP) |
IAB-B026(T) | Recombinant Anti-human FGFR2 Intrabody [Tat] | ICC, Neut, FuncS | scFv-Tat |
There are currently no Customer reviews or questions for TAB-284CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.